Shares of ResMed Inc. RMD inched 0.81% higher to $244.94 Friday, on what proved to be an all-around mixed trading session for ...

Healthcare technology company ResMed's (NYSE: RMD) stock wasn't quite the picture of health on Wednesday. The shares lost ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The S&P 500 ended 0.3% lower on Wednesday, Sept. 18, 2024, as the Federal Reserve announced its first interest-rate cut since ...

Major U.S. indexes were little changed at midday Wednesday, ahead of the Federal Reserve's decision on interest rates.

Wolfe Research downgraded shares of the maker of sleep-apnea airway machines to Underperform from Peer Perform.

ResMed achieved double-digit revenue growth through acquisitions and operating efficiencies, with improving capital ...

ResMed's AirSense 11 platform and myAir app enhance patient engagement and efficiency. Check out why I remain bullish on RMD ...

ResMed faces a 3% drop in share price after concerns over Eli Lilly’s Ozempic, which could impact the demand for CPAP ...

Polark's pessimism stems from concerns that Resmed might be poised to lose market share to its pharmaceutical rival Eli Lilly ...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to ...

Wolfe Research analyst Michael Polark downgraded the rating on Resmed (RMD – Research Report) to a Sell yesterday, setting a price target ...